BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 29584547)

  • 1. Molecular Characterization and Mortality From Breast Cancer in Men.
    Massarweh SA; Sledge GW; Miller DP; McCullough D; Petkov VI; Shak S
    J Clin Oncol; 2018 May; 36(14):1396-1404. PubMed ID: 29584547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distribution of 21-Gene Recurrence Scores in Male Breast Cancer in the United States.
    Altman AM; Kizy S; Yuan J; Denbo JW; Jensen EH; Hui JYC; Tuttle TM; Marmor S
    Ann Surg Oncol; 2018 Aug; 25(8):2296-2302. PubMed ID: 29907942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Prognostic Significance of the Oncotype DX Recurrence Score in T
    Wang M; Wu K; Zhang P; Zhang M; Ding A; Chen H
    Ann Surg Oncol; 2019 May; 26(5):1227-1235. PubMed ID: 30456680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors for Survival and Distribution of 21-Gene Recurrence Score in Patients With Pure Mucinous Breast Cancer: A SEER Population-Based Retrospective Analysis.
    Ding S; Wu J; Lin C; Chen W; Li Y; Shen K; Zhu L
    Clin Breast Cancer; 2019 Feb; 19(1):e66-e73. PubMed ID: 30396812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex Disparity Observed for Oncotype DX Breast Recurrence Score in Predicting Mortality Among Patients with Early Stage ER-Positive Breast Cancer.
    Wang F; Reid S; Zheng W; Pal T; Meszoely I; Mayer IA; Bailey CE; Park BH; Shu XO
    Clin Cancer Res; 2020 Jan; 26(1):101-109. PubMed ID: 31748278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26-30.
    Park S; Han Y; Liu Y; Toriola AT; Peterson LL; Colditz GA; Kim SI; Cho YU; Park BW; Park Y
    Breast Cancer Res; 2019 Oct; 21(1):110. PubMed ID: 31619259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database.
    Roberts MC; Miller DP; Shak S; Petkov VI
    Breast Cancer Res Treat; 2017 Jun; 163(2):303-310. PubMed ID: 28243896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological characteristics, practical treatments, prognosis, and clinical issues of older breast cancer patients in Japan.
    Sawaki M; Yamada A; Kumamaru H; Miyata H; Nakayama K; Shimizu C; Miyashita M; Honma N; Taira N; Saji S
    Breast Cancer; 2021 Jan; 28(1):1-8. PubMed ID: 33219915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology.
    Mamounas EP; Tang G; Paik S; Baehner FL; Liu Q; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Lawrence Wickerham D; Costantino JP; Wolmark N
    Breast Cancer Res Treat; 2018 Feb; 168(1):69-77. PubMed ID: 29128898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive of 21-gene recurrence score assay in non-estrogen receptor-positive and lymph node-negative breast cancer.
    Lu K; Li H; Wu Z; Liu D; Ye H; Xu L; Liu Y
    J BUON; 2018; 23(5):1297-1301. PubMed ID: 30570850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization and prognosis of estrogen receptor-positive/progesterone receptor-negative male breast cancer: a population-based study.
    Wei JL; Zhang JX; Fu DY
    World J Surg Oncol; 2018 Dec; 16(1):236. PubMed ID: 30558615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of pathological features and a 21 gene expression assay in younger versus older women with node-negative endocrine receptor-positive breast cancer.
    Mutonga M; Speedy S; Rademaker A; Liu D; Uthe R; Jain S; Gradishar WJ; Flaum L; Santa-Maria CA
    Breast Cancer Res Treat; 2019 Jul; 176(1):95-100. PubMed ID: 30977026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.
    Li Y; Yang D; Yin X; Zhang X; Huang J; Wu Y; Wang M; Yi Z; Li H; Li H; Ren G
    JAMA Netw Open; 2020 Jan; 3(1):e1918160. PubMed ID: 31899528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Breast Cancer Subtypes on Prognosis of Women with Operable Invasive Breast Cancer: A Population-based Study Using SEER Database.
    Hwang KT; Kim J; Jung J; Chang JH; Chai YJ; Oh SW; Oh S; Kim YA; Park SB; Hwang KR
    Clin Cancer Res; 2019 Mar; 25(6):1970-1979. PubMed ID: 30559169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 21-gene recurrence score testing in the older population with estrogen receptor-positive breast cancer.
    Kizy S; Altman AM; Marmor S; Denbo JW; Jensen EH; Tuttle TM; Hui JYC
    J Geriatr Oncol; 2019 Mar; 10(2):322-329. PubMed ID: 30093354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer.
    Karsten M; Stempel M; Radosa J; Patil S; King TA
    Ann Surg Oncol; 2016 Feb; 23(2):471-6. PubMed ID: 26340863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of marital status on breast cancer survival by age, race, and hormone receptor status: A population-based Study.
    Zhai Z; Zhang F; Zheng Y; Zhou L; Tian T; Lin S; Deng Y; Xu P; Hao Q; Li N; Yang P; Li H; Dai Z
    Cancer Med; 2019 Aug; 8(10):4906-4917. PubMed ID: 31267686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of LN Evaluation with Survival in Women Aged 70 Years or Older With Clinically Node-Negative Hormone Receptor Positive Breast Cancer.
    Chagpar AB; Hatzis C; Pusztai L; DiGiovanna MP; Moran M; Mougalian S; Sanft T; Evans S; Hofstatter E; Wilson LD; Lannin DR
    Ann Surg Oncol; 2017 Oct; 24(10):3073-3081. PubMed ID: 28766195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast.
    Kizy S; Huang JL; Marmor S; Tuttle TM; Hui JYC
    Breast Cancer Res Treat; 2017 Oct; 165(3):757-763. PubMed ID: 28647915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Racial Differences in 21-Gene Recurrence Scores Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer.
    Holowatyj AN; Cote ML; Ruterbusch JJ; Ghanem K; Schwartz AG; Vigneau FD; Gorski DH; Purrington KS
    J Clin Oncol; 2018 Mar; 36(7):652-658. PubMed ID: 29341832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.